Investing in Unpredictable Times: A Conversation with Biotech-CEO-Turned-VC David Mott
• By Kate Rawson
Former MedImmune CEO David Mott discusses the key regulatory and reimbursement risks in drug development. While he sees plenty of venture capitalist money for truly innovative products, there are several areas he tends to avoid at all costs: vaccines, antibiotics, diabetes and-over the longer term-oncology drug development.
By Kate Rawson
The big pharma model is changing. Health care reform is
happening. And the financial markets are still in shock.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
